| Bioactivity | YZL-51N is a selective SIRT7 inhibitor with IC50 value of 12.71 μM. YZL-51N disrupts SIRT7 enzyme activity by occupying the NAD+ binding pocket, thereby weakening DNA damage repair and inhibiting cancer cell survival. YZL-51N possesses anti-tumor activity and can be used in cancer research[1]. |
| Invitro | YZL-51N (0-40 μM, 8 h) 在 HCT116 和 HT29 细胞中呈剂量依赖性的增加 H3K18ac 水平[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> YZL-51N 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | YZL-51N (15 mg/kg, 皮下注射) 在 HCT116 异种移植模型中可使肿瘤体积减小[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 3031072-69-9 |
| Formula | C17H14O7 |
| Molar Mass | 330.29 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kang TS, et al. YZL-51N functions as a selective inhibitor of SIRT7 by NAD+ competition to impede DNA damage repair. iScience. 2024 May 16;27(6):110014. |